Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17798224 | 1.00 | SMARCA2 (0.41) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL17798227 | 1.00 | SMARCA2 (0.41) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL1007106 | 0.88 | SMARCA2 (0.43) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL1007104 | 0.88 | SMARCA2 (0.43) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL1006680 | 0.86 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL1006679 | 0.86 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL17744703 | 0.85 | SMARCA2 (0.41) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL17798206 | 0.85 | SMARCA2 (0.41) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL17744455 | 0.81 | GPR119 (0.42) | SMARCA2SMARCA4PBRM1GPR119ABCB1 | |
| SCHEMBL17744454 | 0.81 | GPR119 (0.42) | SMARCA2SMARCA4PBRM1GPR119ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020718-B1 | NOVEL PDE4 INHIBITOR | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159783-A1 | PDE4 Inhibitor | PDE4A, PDE4B, PDE3B | SMARCA2 2570/4885SMARCA4 1045/4885PBRM1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.